Implantable Drug Delivery Devices Market Report 2026

Implantable Drug Delivery Devices Market Overview

• Implantable Drug Delivery Devices market size has reached to $21.94 billion in 2025 • Expected to grow to $33.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Rising Incidence Of Chronic Diseases Driving Market Growth Due To Increased Demand For Targeted Drug Delivery Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Implantable Drug Delivery Devices Market?

Implantable drug delivery devices are drug delivery systems implanted under the skin that transmit drugs into the bloodstream from a reservoir. These devices facilitate site-specific drug delivery and require smaller doses, thereby minimizing side effects. The main products of implantable drug delivery devices is contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and others. Spinal implants are devices that are used by surgeons while performing surgery to treat deformity, stabilize and strengthen the spine, and facilitate fusion. The technologies involved are diffusion, osmosis, magnetic, and others. The various applications involved are contraception, ophthalmology, cardiovascular, diabetes, oncology, autoimmune diseases, and others.

What Is The Implantable Drug Delivery Devices Market Growth Forecast?

The implantable drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $33.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of smart implantable devices, rising demand for personalized drug delivery, expansion of biodegradable implant technologies, growing investments in combination drug-device products, increasing regulatory approvals for implantable therapies. Major trends in the forecast period include increasing adoption of controlled-release implant systems, rising use of bio-absorbable implant materials, growing demand for site-specific drug delivery, expansion of miniaturized implantable devices, enhanced focus on patient compliance.

Global Implantable Drug Delivery Devices Market Segmentation

1) By Product: Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion Pumps, Other Applications 2) By Technology: Diffusion, Osmotic, Magnetic, Other Technologies 3) By Application: Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, Other Applications Subsegments: 1) By Contraceptive Implants: Hormonal Contraceptive Implants, Non-hormonal Contraceptive Implants 2) By Spinal Implants: Biodegradable Spinal Implants, Non-biodegradable Spinal Implants 3) By Brachytherapy Seeds: Iodine-125 Seeds, Palladium-103 Seeds, Cesium-131 Seeds, Other Brachytherapy Seeds 4) By Drug-Eluting Stents: Coronary Drug-Eluting Stents, Peripheral Drug-Eluting Stents 5) By Bio-absorbable Stents: Polymer-based Bio-absorbable Stents, Metal-based Bio-absorbable Stents 6) By Intraocular Stents: Glaucoma Intraocular Stents, Cataract Surgery Intraocular Stents 7) By Infusion Pumps: Insulin Pumps, Chemotherapy Infusion Pumps, Pain Management Infusion Pumps, Other Infusion Pumps 8) By Other Applications: Implantable Reservoirs, Implantable Micro-pumps, Implantable Drug Elution Devices

What Are The Drivers Of The Implantable Drug Delivery Devices Market?

The growing incidence of chronic diseases is expected to propel the growth of the implantable drug delivery devices market going forward. Chronic diseases are long-lasting medical conditions that persist over an extended period of time, typically for three months or more. The rising incidence of chronic diseases is due to widespread unhealthy lifestyle behaviors such as poor nutrition, physical inactivity, and tobacco use, which significantly increase the risk of developing non-communicable diseases globally. Implantable drug delivery devices are increasingly used to provide long-term, controlled medication administration for chronic diseases and improve patient compliance and treatment effectiveness. For instance, in August 2025, according to the Centers for Disease Control and Prevention, a Switzerland-based public health agency, 90% of the nation’s 4.9 trillion dollars in annual health care spending is attributed to individuals with chronic and mental health conditions, with more than 84,000 Americans dying each year from heart disease or stroke and the costs associated with cardiovascular diseases projected to reach roughly 2 trillion dollars by 2050. Therefore, the growing incidence of chronic diseases is driving the growth of the implantable drug delivery devices industry. The growing healthcare expenditure is expected to propel the growth of the implantable drug delivery devices market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services, products, and public health activities within a country or system, including hospital care, physician services, medicines, medical devices, long-term care, and preventive programs. Healthcare expenditure is growing as the rising burden of chronic diseases requires continuous treatment, long-term medication, and frequent clinical visits, significantly increasing overall spending. Growing healthcare expenditure supports the implantable drug delivery devices market by enabling wider adoption of advanced, long-term treatment technologies. For instance, in April 2025, according to the Office for National Statistics, a UK-based government department, between 2023 and 2024, overall healthcare spending increased by 6.5% in nominal terms, and by 2.4% in real terms after accounting for inflation. Therefore, the growing healthcare expenditure is driving the growth of the implantable drug delivery devices industry.

Key Players In The Global Implantable Drug Delivery Devices Market

Major companies operating in the implantable drug delivery devices market are AbbVie Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck & Co. Inc., Genentech Inc, EyePoint Pharmaceuticals Inc., DSM Biomedical, Delpor Inc., Teleflex Incorporated, Biotronik Inc., Alcon Inc., Terumo Corporation, Endologix Inc., Innocoll Biotherapeutics, Atossa Therapeutics Inc., Intersect ENT, Microchips Biotech, Theradaptive Inc., CollPlant, Intarcia Therapeutics, Glaukos Corporation

What Are Latest Mergers And Acquisitions In The Implantable Drug Delivery Devices Market?

In May 2024, Arecor, a UK-based biopharmaceutical company specializing in novel formulations, partnered with Medtronic, to develop a highly concentrated, yet stable, liquid formulation of an undisclosed Medtronic therapeutic product. Through this collaboration, Medtronic will fund the formulation and development of an Arestat-enabled insulin tailored for implantable delivery, enhancing therapeutic precision and patient outcomes. Medtronic, a US-based health technology company, to develop a high-concentration, thermostable insulin for use in next-generation implantable pumps.

Regional Outlook

North America was the largest region in the implantable drug delivery devices market in 2025. Asia-Pacific was the second-largest region in the implantable drug delivery devices market report. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

What Defines the Implantable Drug Delivery Devices Market?

The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.